We are live on
!
Find out more
GTC
Ghost Tree Capital Portfolio holdings
AUM
$331M
1-Year Est. Return
70.11%
This Fund
S&P 500
This Quarter
Est. Return
+10.87%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$309M
AUM Growth
+$30.5M
(+11%)
Cap. Flow
+$16.2M
Cap. Flow
% of AUM
5.24%
Top 10 Holdings %
Top 10 Hldgs %
34.98%
Holding
101
New
36
Increased
15
Reduced
14
Closed
32
Top Buys
| 1 |
Biogen
BIIB
|
+$12M |
| 2 |
ENDP
Endo International plc
ENDP
|
+$10.4M |
| 3 |
Intuitive Surgical
ISRG
|
+$10.1M |
| 4 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$8.63M |
| 5 |
GNMK
GenMark Diagnostics, Inc
GNMK
|
+$7.56M |
Top Sells
| 1 |
Zimmer Biomet
ZBH
|
+$11.8M |
| 2 |
Community Health Systems
CYH
|
+$7.84M |
| 3 |
ZSPH
ZS PHARMA INC COMS TK (DE)
ZSPH
|
+$6.94M |
| 4 |
CELG
Celgene Corp
CELG
|
+$6.92M |
| 5 |
DYAX
DYAX CORPORATION
DYAX
|
+$5.86M |
Sector Composition
| 1 | Healthcare | 85.5% |
| 2 | Financials | 1.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AGN
1
DELISTED
Allergan plc
AGN
| $13.7M | 4.43% |
45,000
+10,000
| +29% | +$2.98M |
|
|
AVDL
2
DELISTED
Avadel Pharmaceuticals
AVDL
| $12.2M | 3.95% |
575,000
+375,000
| +188% | +$6.72M |
|
|
3
Biogen
BIIB
$30.4B
| $12.1M | 3.93% |
+30,000
| New | +$12M |
|
|
NUVA
4
DELISTED
NuVasive, Inc.
NUVA
| $11.1M | 3.61% |
235,000
+75,000
| +47% | +$3.51M |
|
5
Alnylam Pharmaceuticals
ALNY
$35.7B
| $10.8M | 3.5% |
90,000
+50,000
| +125% | +$5.98M |
|
|
FPRX
6
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $10.6M | 3.42% |
425,000
+325,000
| +325% | +$7.24M |
|
|
7
Intuitive Surgical
ISRG
$122B
| $9.69M | 3.14% |
+180,000
| New | +$10.1M |
|
|
ENDP
8
DELISTED
Endo International plc
ENDP
| $9.56M | 3.1% |
+120,000
| New | +$10.4M |
|
|
GWPH
9
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $9.21M | 2.99% |
75,000
+30,000
| +67% | +$3.4M |
|
|
ALXN
10
DELISTED
Alexion Pharmaceuticals
ALXN
| $9.04M | 2.93% |
+50,000
| New | +$8.63M |
|
|
PTLA
11
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $7.74M | 2.51% |
170,000
-10,000
| -6% | -$402K |
|
12
Vertex Pharmaceuticals
VRTX
$123B
| $7.41M | 2.4% |
+60,000
| New | +$7.56M |
|
|
HZNP
13
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $6.95M | 2.25% |
+200,000
| New | +$6.1M |
|
|
GNMK
14
DELISTED
GenMark Diagnostics, Inc
GNMK
| $6.79M | 2.2% |
+750,000
| New | +$7.56M |
|
|
NSTG
15
DELISTED
NanoString Technologies, Inc.
NSTG
| $6.17M | 2% |
400,000
+65,000
| +19% | +$869K |
|
|
ESPR
16
DELISTED
Esperion Therapeutics
ESPR
| $6.13M | 1.99% |
+75,000
| New | +$7.34M |
|
|
CPHD
17
DELISTED
Cepheid Inc
CPHD
| $6.12M | 1.98% |
100,000
+25,000
| +33% | +$1.43M |
|
18
Cigna
CI
$74.5B
| $6.08M | 1.97% |
+37,500
| New | +$5.18M |
|
|
EPZM
19
DELISTED
Epizyme, Inc
EPZM
| $6M | 1.94% |
250,000
+135,000
| +117% | +$2.6M |
|
20
Neurocrine Biosciences
NBIX
$17.2B
| $5.85M | 1.9% |
+122,500
| New | +$5.19M |
|
|
FOLD
21
DELISTED
Amicus Therapeutics
FOLD
| $5.31M | 1.72% |
375,000
+25,000
| +7% | +$301K |
|
22
Atara Biotherapeutics
ATRA
$75.6M
| $5.28M | 1.71% |
+4,000
| New | +$4.59M |
|
23
DexCom
DXCM
$29.6B
| $5.2M | 1.68% |
+260,000
| New | +$4.57M |
|
|
AET
24
DELISTED
Aetna Inc
AET
| $5.1M | 1.65% |
+40,000
| New | +$4.57M |
|
|
ANAC
25
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
| $5.03M | 1.63% |
+65,000
| New | +$4.26M |
|
Similar funds
SF
AFS
SFA
E
OHCM
MC
BRA
S
Ghost Tree Capital's Q2 2015 Portfolio in Review
As of Q2 2015, Ghost Tree Capital held 101 positions worth $309M, up 11% from $278M the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Ghost Tree Capital deployed $16.2M of net new capital in Q2 2015, opening 36 new positions and adding to 15 existing holdings. Its largest new stake was Biogen: 30,000 shares worth $12.1M.
By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 72% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was Sage Therapeutics, an estimated $4.02M trimmed.
- Ghost Tree Capital's largest Q2 2015 buy was Biogen: 30,000 shares worth $12.1M.
- Ghost Tree Capital added most to Five Prime Therapeutics, Inc. in Q2 2015, an estimated $7.24M increase.
- Ghost Tree Capital's biggest Q2 2015 reduction was Sage Therapeutics, cutting an estimated $4.02M.
- Ghost Tree Capital fully exited Zimmer Biomet in Q2 2015, selling an estimated $11.8M.
- Ghost Tree Capital's ten largest holdings make up 35% of its $309M portfolio in Q2 2015.
- Ghost Tree Capital opened 36 new positions and closed 32 in Q2 2015.
- Ghost Tree Capital's portfolio value rose 11% quarter-over-quarter to $309M.
Based on Ghost Tree Capital's 13F filing for Q2 2015, filed 14 Aug 2015.